Sirukumab Completed Phase 2 Trials for Major Depressive Disorder (MDD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02473289An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder